Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
A. Rastogi and J. L. J. Jr
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
J. F. E. Mann, P. Rossing, et al.
Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
N. Snelder, R. Heinig, et al.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
H. M. Colhoun, I. Lingvay, et al.
Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial
A. Podadera-herreros, A. P. A. Larriva, et al.
